Assignment of Weight-Based Antibody Units for Seven Additional Serotypes to a Human Pneumococcal Standard Reference Serum, 007sp.
The pneumococcal enzyme-linked immunosorbent assay (ELISA) reference standard serum, lot 89SF, has been in use since 1990 and was replaced in 2013 with a new reference standard, 007sp, that is projected to be available for the next 25 years. 007sp was generated under an FDA-approved clinical protocol; 278 adult volunteers were immunized with the 23-valent unconjugated polysaccharide vaccine Pneumovax II, and a unit of blood was obtained twice from each immunized subject within 120 days following immunization. Pooled serum was prepared from the plasma of 262 subjects, filled at 6 ml per vial, and lyophilized. Five independent laboratories participated in bridging the serotype-specific IgG assignments for 89SF to the new reference standard, 007sp, to establish equivalent reference values for 13 pneumococcal capsular serotypes (1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) by using the WHO reference ELISA. In a second study involving three laboratories, a similar protocol was used to assign weight-based IgG concentrations in micrograms per ml to 007sp of seven serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) also present in the 23-valent pneumococcal unconjugated polysaccharide vaccine. In addition, the IgG assignments for a 12-member WHO quality control (QC) serum panel were also extended to cover these seven serotypes. Agreement was excellent, with a concordance correlation coefficient (r(c)) of >0.996 when each laboratory was compared to the assigned values for the 12 WHO QC serum samples. There are four remaining pneumococcal serotypes (2, 9N, 17F, and 20) found in Pneumovax II for which IgG assignments exist for 89SF and remain to be bridged.
University College London Institute of Child Health, London, United Kingdom d.goldblatt@ucl.ac.uk.
D
D
Goldblatt
Pfizer, Inc., Pearl River, New York, USA.
C Y
CY
Tan
University College London Institute of Child Health, London, United Kingdom.
P
P
Burbidge
Pfizer, Inc., Pearl River, New York, USA.
S
S
McElhiney
Pfizer, Inc., Pearl River, New York, USA.
L
L
McLaughlin
Pfizer, Inc., Pearl River, New York, USA.
R
R
Tucker
Universitätsklinikum Erlangen, Erlangen, Germany.
M
M
Rauh
Pfizer, Inc., Pearl River, New York, USA.
M
M
Sidhu
Pfizer, Inc., Pearl River, New York, USA.
P C
PC
Giardina
D000328:Adult; D000907:Antibodies, Bacterial / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006801:Humans; D007114:Immunization; D007074:Immunoglobulin G / Q000097:blood*; D022242:Pneumococcal Vaccines / Q000276:immunology*; D011786:Quality Control; D012015:Reference Standards; D012016:Reference Values; D065288:Serogroup; D012703:Serotyping; D014944:World Health Organization
C414006:23-valent pneumococcal capsular polysaccharide vaccine; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines